Oral contraceptive pills and long-term metabolic risk

A recent study published in the journal Nutrients found that some types of oral contraceptives may impair the sugar metabolism in healthy women.

The study included 21 healthy and non-obese women between the ages 18-40. The women were using combined monophasic OCP for more than three months. The OCPs contained ethinylestradiol (EE) and the progestin component varied in the androgenic characteristics, some androgenic and others antiandrogenic. 

The authors of the study reported markers of blood sugar (glucose, insulin and C-peptide). The markers were evaluated in participants of the study before 60 g glucose drink (fasting) and for 4 hours after drinking the sugar. The measurements were done during the “active” pill phase and once during the “inactive” (hormone-free) pill phase.

Although the fasting blood sugar levels were not affected in androgenic pill users, glucose, insulin, and C peptide responses to an oral glucose bolus were ~100% ~50%, ~44% greater. This intolerance to the sugar was noticeable during the active pill phase compared to the hormonal free or inactive pill phase.

The authors of the study concluded that that androgenic component of the combined oral contraceptive pills formulations may impair glucose tolerance and increase insulin resistance. This rising incidence of these adverse effects on glucose tolerance and insulin resistance contribute to detrimental of metabolic health and is linked to an increased prevalence of cardiometabolic diseases in women. Young women need to be informed of the metabolic risk associated to the use of combined hormonal contraceptives.

Fertility awareness methods and fertility appreciation can help young women to monitor health biomarkers of hormonal and metabolic activity and are healthier and safer alternatives to oral contraceptive pills.

Leave a Reply

You must be logged in to post a comment.